LIMN

+ Watchlist + Portfolio

Liminatus Pharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.11
52-Week Range: $0.10 – $4.06
Market Cap: $7.56M
P/E (TTM): —
EPS (TTM): -0.48
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -95.65%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.12
Debt/Equity: 4.80
Total Debt: $1.44M
Free Cash Flow: $-10.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.93M

LIMN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.85M	$3.76M	$2.69M	$0.00
Selling, General & Admin	$856.00K	$1.06M	$644.62K	$2.97M
Operating Expenses	$2.71M	$4.82M	$3.33M	$2.97M
Operating Income	-$2.71M	-$4.82M	-$3.33M	-$2.97M
EBITDA	-$2.71M	-$4.81M	-$3.21M	-$9.99M
Pretax Income	-$2.93M	-$4.98M	-$3.55M	-$10.21M
Net Income	-$2.93M	-$4.98M	-$3.55M	-$10.21M
Diluted EPS	-0.11	-0.19	-0.14	-0.43
Diluted Shares	26.01M	26.01M	26.01M	23.75M

LIMN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.05M	$434.00K	$56.32K	$337.65K
Receivables	$100.00K	$945.00K	$3.67M	$0.00
Current Assets	$6.84M	$2.24M	$5.28M	$500.57K
Total Assets	$6.84M	$2.24M	$5.41M	$512.79K
Current Liabilities	$17.65M	$18.04M	$24.75M	$10.30M
Total Debt	$16.50M	$16.05M	$19.97M	$1.44M
Total Liabilities	$17.65M	$18.04M	$24.75M	$10.33M
Retained Earnings	-$20.14M	-$25.12M	-$28.67M	-$38.87M
Shareholders' Equity	$0.00	$0.00	-$19.34M	-$9.81M
Working Capital	-$10.81M	-$15.79M	-$19.47M	-$9.80M
Net Debt	$11.45M	$15.62M	$19.92M	$1.10M

LIMN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$869.00K	-$3.35M	-$1.45M	-$9.96M
Capital Expenditure	—	—	—	-$13.11K
Free Cash Flow	-$869.00K	-$3.35M	-$1.45M	-$9.98M
Depreciation & Amortisation	—	—	$0.00	$1.83K
Investing Cash Flow	$0.00	-$819.00K	-$2.85M	-$788.11K
Financing Cash Flow	$5.92M	-$450.00K	$3.92M	$11.03M
Share Repurchases	-$700.00K	$0.00	—	—
Net Change in Cash	$5.05M	-$4.61M	-$378.07K	$281.34K

LIMN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	—	$0.00	$0.00	$0.00
Research & Development	$0.00	—	$0.00	$0.00	$400.00K
Selling, General & Admin	$264.22K	—	$701.17K	$884.21K	$700.90K
Operating Expenses	$264.22K	—	$701.17K	$884.21K	$1.10M
Operating Income	-$264.22K	—	-$701.17K	-$884.21K	-$1.10M
EBITDA	-$212.01K	$176.32K	-$1.80M	-$8.15M	-$1.10M
Pretax Income	-$327.53K	—	-$1.82M	-$8.17M	-$1.12M
Net Income	-$327.53K	—	-$1.82M	-$8.17M	-$1.12M
Diluted EPS	-0.01	—	-0.07	—	-0.03
Diluted Shares	26.01M	—	27.01M	—	36.00M

LIMN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	—	—	$724.50K	$337.65K	$1.91M
Receivables	—	—	$0.00	$0.00	—
Current Assets	—	—	$1.20M	$500.57K	$2.78M
Total Assets	$0.00	—	$1.34M	$512.79K	$2.79M
Current Liabilities	$1.06K	—	$2.86M	$10.30M	$2.89M
Total Debt	—	—	$1.44M	$1.44M	$1.44M
Total Liabilities	$1.06K	—	$2.99M	$10.33M	$2.92M
Retained Earnings	-$1.06K	—	-$30.70M	-$38.87M	-$40.00M
Shareholders' Equity	-$1.06K	—	-$1.65M	-$9.81M	-$132.60K
Working Capital	—	—	-$1.66M	-$9.80M	-$110.88K
Net Debt	—	—	$718.00K	$1.10M	—

LIMN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$159.39K	-$8.82M	-$600.61K	-$386.85K	-$2.02M
Free Cash Flow	-$159.39K	-$8.82M	-$613.72K	-$386.85K	-$2.02M
Depreciation & Amortisation	$0.00	$743.00	$542.00	$543.00	$518.00
Investing Cash Flow	-$575.00K	-$200.00K	-$13.11K	$0.00	$0.00
Financing Cash Flow	$713.00K	$10.32M	$0.00	$0.00	$3.59M
Net Change in Cash	-$21.39K	$1.30M	-$613.72K	-$386.85K	$1.57M

Market Snapshot

About

Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company's pipeline includes novel drug candidates targeting unmet medical needs in conditions such as Alzheimer's disease and other cognitive disorders. Liminatus utilizes advanced research platforms to identify and develop small molecule therapeutics with improved efficacy and safety profiles.